

Effets of Secondary Trimester Maternal Serum Fetoprotein, Human Chorionic Gonadotropin, Unconjugated Oestriol, Inhibin-A Levels on the Results of Pregnancy

By YILDA ARZU ABA



Effets of Secondary Trimester Maternal Serum Fetoprotein, Human Chorionic Gonadotropin, Unconjugated Oestriol, Inhibin-A Levels on the Results of Pregnancy

Kemal Dinc¹
Ramazan Ozyurt¹
Aytek Sık²
Serkan Kumbasar³
Yasam Kemal Akpak⁴
Yilda Arzu Aba⁵

Abstract

In our study it was aimed to research the relations between pregnancy complications and frequencies of maternal and fetal complications which can be observed after the further follow-ups with biochemical indicators in gravid individuals whom found to be risky in quad tes⁵ 20 patients who applied and had their labors conducted in our hospital and took quad test AFP (alpha fetoprotein), HCG (human chorionic gonadotropin), uE3 (unconjugated estriol), inhibin-A are included in our study. Conclusions planned to be obtained in this study are, IUGR (intrauterine growth deficiency), macrosomia, gestational diabetes, preeclampsia and preterm birth. 64 (% 53, 4) out of 120 patients participated in the study had normal labors while 56 (%46, 6) of the patients had labors with caesarean birth. On 70 (%58.3) patients whom did not develop obstetric complications, AFP value calculated as average as 1.00 ± 0.74 MoM, uE3 value calculated as 0.89 ± 0.4 MoM, hCg value calculated as 0.97 ± 0.5 MoM and inhibin A value calculated as an average of 0.95 ± 0.5 MoM. On 50 (%41.6) patients whom developed obstetric complications, AFP value found as average of $1,06 \pm 0,74$, uE3 value found as 0.96 ± 0.39 MoM, hCG value found as 0.99 ± 0.77 MoM and Inhibin A value found as 1.023 ± 0.62 MoM. There were no significant deviation between the cases with obstetric complications and cases without obstetric complications in terms of AFP, uE3, HCG and Inhibin A values. There were no

2

¹ Op. Dr. Department of Obstetrics and Gynecology, Istanbul Research and Education Hospital, Istanbul, Turkey, xxdoktor15@ynet.com, atasagun02@hotmail.com

² Assistant Professor, Ph.D., Department of Obstetrics and Gynecology, Istanbul Aydın University, Istanbul, Turkey, bulataytek@hotmail.com

³ Op. Dr. Department of Obstetrics and Gynecology, Sakarya Research and Education Hospital, Sakarya, Turkey, doktor1977@hotmail.com

⁴ Op. Dr. Department of Obstetrics and Gynecology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, yasamaster@gmail.com

⁵ Assistant Professor, Ph.D., Bandırma Onyedi Eylül University, Health Science Faculty, Faculty of Health Science, Nursing Department, Balıkesir, Turkey, yildarzum@hotmail.com

significant relation between threshold values of AFP, HCG, uE3 and inhibin A which are used in quad test as secondary trimester serum indicators in low risk populations and pregnancy complications.

Keywords: Serum scan test; alfa-fetoprotein; human chorionic gonadotropin; inhibin A; bad obstetric results.

5

6

7 Introduction

8

9 During Antenatal follow up, using biochemical screen tests besides ultrasonography for
10 diagnosing fetal anomalies provided better pregnancy results. Besides assignation of risk for
11 chromosomal and structural anomalies, biochemical indicators used in screen tests found to be
12 used for forecasting pregnancy complications (Boby & Vile, 2005; 152). In the early 1970s the
13 only method for diagnosing Down syndrome in fetus was the age of the mother; all the women
14 at the age of 35 or above were suggested to conduct amniocenteses. During 1980s secondary
15 trimester mother serum biochemical indicators added to the age of the mother as a new screening
16 method (James et al., 2008). At the start of the usage of triple test Down syndrome diagnosis
17 rate obtained as %70. the 16th week of the pregnancy median values of AFP (alpha fetoprotein),
18 uE3 (unconjugated estriol), hCG(human chorionic gonadotropin) concentrations found to be
19 different in the gravids carrying trisomy 21 fetus compared to normal fetus carrying mothers.
20 Screen test called as "triple test" was suggested for by considering that these hormones might be
21 used for screening the risky groups. Different indicators combined in order to increase the
22 sensibility of the biochemical screen test. Addition of Inhibin-A to triple screen test is the most
23 commonly used one. On the pregnancy with Down syndrome it was reported that though
24 inhibit A increases it cannot be used for calculating the trisomy 18 risk (Kafkaslı, 2004). On the
25 gravids diagnosed with lower levels of PAPP-A (Pregnancy-Associated Plasma
26 Protein), complications as intrauterine growth deficiency (IUGR), premature birth, preeclampsia
27 and stillbirth are observed to be increasing compared to gravids which are not diagnosed with
28 lower levels of PAPP-A (Smith et. al., 2002; 1762) . On the gravids diagnosed with higher β -hCG
29 levels, IUGR, preterm birth, preeclampsia and fetal loss rates observed to be increasing compared
30 to gravids with normal β -hCG levels (Chandra et. al., 2003). Thus there are some studies
31 reporting the relation between lower estriol levels and further preeclampsia, it is not a sensitive
32 indicator (Lindheimer et. al., 2003). Human placenta, decidua and fetal membranes are the major
33 areas for production of mother serum, amniotic fluid, inhibin A and inhibin B in cord blood.
34 Inhibin A found in mother's blood mainly synthesized by placenta (Wallace et. al., 1997). Neural

35 tube deficiency (NTD) is the secondary commonly observed fetal congenital malformation
36 following cardia anomalies (Knoshnood et. al., 2011). Alpha fetoprotein is used in NTD
37 screening for over 30 years while ultrasonography (USG) is used for diagnosis. (Krantz et. al.,
38 2010). As skin to be intact on %10 of the NTDs, while higher MSAFP values are not found in
39 these cases, it is not efficient for NTD screening (Cameron & Moran, 2009).

40

41 **Material and Methods**

42 In our study it was aimed to study the relations between complications of pregnancies
43 and frequencies of maternal and fetal complications which can be observed after the further
44 follow-ups with biochemical indicators in gravids whom found to be risky in quad test for Down
45 syndrome.

46 120 patients which are applied to pregnancy policlinic of Istanbul Training and Research
47 Hospital between 2 January 2012 and 2 July 2013 and conducted quad test (AFP, hCG, uE3)
48 (AFP: Alfa-Fetoprotein, hCG: Human Chorionic Gonadotropin, uE3:unconjugated oestriol),
49 inhibin-A) and had their labors in our hospital were included in the study. Quad test results and
50 obstetric complications of the patients participated in the study were compared. Study conducted
51 in Istanbul training and research hospital perinatology and delivery unit following the approval
52 from Hospital Training and Planning Committee and Committee of Ethics. Within the
53 indicated dates, patients considered within the scope of the study were informed and included in
54 the study following their signed approval on the form of approval.

55 Criterias for inclusion in our study, are singleton gravids who took quad test between
56 16th and 20th week as per their last menstruation date, no presence of miscarriage risk (vaginal
57 bleeding, pain etc.), no exposure to medication or radiation during the pregnancy within study
58 period, no consanguineous marriage, no presence of blood incompatibility, no history of baby
59 birth with fetal anomaly and not to be aged between 16 and 42. Exclusion criterias in our study
60 are multiple pregnancy, no observation of fetal hearth beat between 16th and 20th weeks, fetal
61 anomaly diagnosed in ultrasound, gravids who did not conduct labor in our hospital, individuals
62 diagnosed with diabetes in presentational period, presence of bad obstetric history and gravids
63 below 16 years of age and older than 42 years of age. In addition to the quad test markers of the
64 120 gravids within in the criterias of the study; obstetric histories, physical examinations, fetal
65 obstetric ultrasonography, amniotic fluid indexes, birth types, Antenatal and postnatal pregnancy
66 complications (preeclampsia, early membrane rupture, preterm birth, Small Gestational Age
67 (SGA), gestational diabetes Mellitus (GDM)) biochemical results were searched from the patients'

68 files. Labor types and fetal birth weight information were collected from birth registrations by
69 retrospective inspections. Information of the patients were evaluated after the labor.

70 Findings planned to be obtained as a result of this study comprised of intrauterine growth
71 deficiency (IUGR), macrosomia, gestational Diabetes (GDM), preeclampsia and preterm birth.
72 Babies born below the 10th percentile as per the pregnancy week are accepted as small
73 gestational age (SGA). Macrosomia as per the pregnancy age was used for defining the newborns
74 which were born over 90th percentile of gestation week in terms of birth weight. Heavy
75 preeclampsia, if no preeclampsia proteinuria were present, defined as the presence of symptoms
76 and/or findings or 1+ or more proteinuria and blood pressure over 140/90mmHg. Birth before
77 the 37th pregnancy week defined as preterm birth. 2 of the 100 gram oral glucose tolerance test
78 results to be higher as per ACOG criterias accepted as gestational diabetes. PPRM (Preterm
79 premature rapture of membranes) described as the arrival of amnion fluid as a result of the
80 spontaneous tearing of amnion membrane before 1 or more hours prior to start of the activity
81 before 37th pregnancy week.

82

83 **Statistical Analysis**

84

85 Descriptive and analytical statistical analysis were conducted for all the patients using
86 SPSS 15.0 (Statistical Package for the Social Sciences Inc.; Chicago, IL, ABD) software. For
87 continuous measured variables, descriptive statistics were presented as average \pm standard
88 deviation as presenting minimum and maximum values while quantitative variables were
89 presented as number of cases and percentiles(%). Presence of statistically significant deviation
90 between groups in terms of normal distributed continuously measured variables were evaluated
91 with T test while the importance of the deviance between the groups for non-normal distributed
92 continuously measured variables were evaluated with Mann Whitney U test. Study groups
93 evaluated in two groups as gravids with complications and gravids without complications during
94 these analysis. In order to determine the more efficient factor in preeclampsia, preterm birth and
95 IUGG, logistic regression analysis conducted. $P < 0.05$ accepted as statistically significant.

96

97 **Results**

98

99 Relations between pregnancy complications and secondary trimester screening results
100 with HCG, AFP, uE3 and Inhibin a MoM values for 120 cases were evaluated. While IUGR were
101 included in macrosomia, preterm birth, preeclampsia, gestational diabetes and gravids developed
102 fetal distress complication group, gravids without problems in antenatal follow-up are comprised

103 the group of patients without complications. 50 (41.6%) of the patients experienced problems in
104 antenatal follow-ups while 70 (58.3%) of the patients did not develop complications. As we look
105 on the demographical specifications of the cases included in the study, average age in the group
106 without complications found as 29.46 ± 5.87 and average age in the complication group found as
107 27.74 ± 5.92 . Average weight of the non-complications found as 65.52 ± 10.32 and BMI were
108 found as 25.08 ± 4.14 and average weight for the complications group found as 64.26 ± 8.95 and
109 BMI was found as 24.76 ± 3.97 . Age of the mother, weight, height and BMI (body mass index)
110 values for the complication group and non-complication groups are given in Table 1. There is no
111 significant deviance between the cases in terms of age of mother, weight, height and BMI
112 ($p > 0.05$).

113 **Table 1. Age of Mother, weight, height and BMI values for the complication group and**
114 **non-complication groups.**
115

	Complication Unpresented		Complication Present		p
	M	sd	M	sd	
Age	29.46	5.87	27.74	5.92	,115
Weight	65.52	10.32	64.26	8.95	,488
Height	161.85	6.10	161.40	6.52	,701
BMI	25.08	4.14	24.76	3.97	,680

116 **BMI: Body Mass Index, M: Mean, SD: standard deviation**

117 64 (53.4%) out of 120 patients participated in the study had normal childbirths while 56
118 (46.6%) of the patients had childbirths with caesarean birth. As the genders of the newborns
119 considered for the 120 cases participated in the study, 59 (49.1%) male babies and 61 (50.8%)
120 female babies were given birth. Distribution of the birth type and gender are given in table for
121 complication and non-complication groups in Table 2. There is no significant deviation between
122 the complication and non-complication group in terms of birth type and gender distribution
123 ($p > 0.05$).

124 **Table 2. Distribution of birth type and gender between complication and non-**
125 **complication group.**

	Complication Unpresented		Complication Present		p
	n	%	n	%	
Birth Type					
NSD	40	57.1	24	48.0	
Caesarean	30	42.9	26	52.0	0.332
Sex					
Male	34	48.6	25	50.0	
Female	36	51.4	25	50.0	0.877

126 NSD: Normal Spontaneous Birth

127

128 2 of the cases were observed with preeclampsia (4%), 5 were observed with IUGR (10%),
129 1 observed with early membrane rupture (EMR) (2%), 20 observed with preterm activity (40%), 7
130 observed with fetal distress, 6 observed with GDM (12%) and 9 observed with macrosomia
131 (18%) out of 120 gravids participated in the study (Table 3).


132 **Table 3. Pregnancy Complication and Frequency**

Complication	n	%
IUGR	5	10.0
Preeclampsia	2	4.0
EMR	1	2.0
Fetal Distress	7	14.0
GDM	6	12.0
Preterm Activity	20	40.0
Macrosomia	9	18.0
Total	50	100.0

133 IUGR: Intrauterine Growth Deficiency EMR: Early Membrane Rupture GDM: Gestational Diabetes Mellitus

134

135 **Figure 1. ROC curve**



4 area below the curve

AFP: Alfa-Fetoprotein HCG: Human Chorionic Gonadotropin, uE3: Unconjugated oestriol, ROC: Receiver Operating Characteric

Table 4. Relation between AFP, uE3, HCG and inhibin-A values and complication development in ROC analysis

	Area	Std. Error	Asp. Sig.	Asymptomatic 95% Lower Limit	confidence interval Upper Limit
AFP	.476	.054	.650	.370	.581
uE3	.559	.053	.275	.454	.663
hCG	.493	.054	.894	.386	.599
4 Inhibin A	.521	.053	.699	.416	.625

143 AFP: Alfa-Fetoprotein HCG: Human chorionic Gonadotropin uE3: unconjugated oestriol

144

145 No significant deviation between AFP, uE3, HCG and inhibin-A values and complication
146 development found within the conducted ROC analysis. As AFP MoM threshold values
147 considered as 1.5, 2.0 and 2.5, relation between complication observation frequency and AFP
148 MoM values over threshold values found to be insignificant. ($p=0.268$ $p=0.224$ $p=0.229$
149 respectively). As HCG MOM threshold values considered as 1.5 and 2.0, relation between
150 complication observation frequency and HCG MOM values over these threshold values found to
151 insignificant. ($p=0.479$, $p=0.872$). As threshold value for uE3 MoM considered as 0.8 relation
152 between complication observation frequency and uE3 MoM values over these threshold values
153 found to significant. ($p=0.001$). In other words, as the threshold values of uE3 MoM values
154 considered as 0.6, 0.7, 0.8 and 0.9 a significant relation between complication observation
155 frequency and uE3 MoM values over these threshold values were identified. ($p=0.129$)

156 As threshold values of Inhibin-A MoM considered as 1.5 and 2.0, relation between
157 complication observation frequency and HCG MoM values over these threshold values found to
158 be insignificant ($p=0.87$, $p=0.910$ respectively).

159 Out of 120 cases participated in the study for 70(%58.3) non-complication cases average
160 AFP value calculated as $1,00 \pm 0,74$ MoM, uE3 value calculated as $0,89 \pm 0,4$ MoM, hCG value
161 calculated as $0,97 \pm 0,5$ MoM and average Inhibin A value calculated as $0,95 \pm 0,5$ MoM. For 50
162 (%41.6) cases developed complications, average AFP value calculated as $1,06 \pm 0,74$, uE3 value
163 calculated as $0,96 \pm 0,39$ MoM, hCG value calculated as $0,99 \pm 0,77$ MoM and Inhibin-A value
164 calculated as $1,023 \pm 0,62$ MoM. There is no significant deviation between complication and
165 non-complication group in terms of AFP, uE3, HCG and Inhibin-A values ($p>0, 05$) (Table 5).

166

167 **Table 5. Comparison of complication and non-complication groups in terms of AFP,**
 168 **uE3, HCG and Inhibin A values**

	Complication Unpresented (n=70)		Complication Present (n=50)		p
	M	sd	M	sd	
AFP	1.0080	,7440	1,069	,7427	,615
uE3	.8955	,4089	,9668	,3900	,274
hCG	.9734	,5482	,9942	,7717	,850
Inhibin A	.9568	,5281	1,0235	,6251	,699

169 AFP: Alfa-Fetoprotein, HCG: Human Chorionic Gonadotropin, uE3: Unconjugated oestriol M: Mean
 170

171

171 Discussion

172

173

174

175

176

177

178

179

Purpose of the screening tests is to screen biggest population possible and diagnose the high risk pregnancies in terms of genetic diseases. For this purpose, ultrasonography and analysis methods of biochemical indicators in maternal blood are commonly used in present times. Thus there is no agreement over the prenatal screen tests, a lot of studies still conducted on this subject. Conducted studies focused either on developing a new protocol or specificity and sensitivity in birth anomalies. Threshold values of secondary trimester MSAFP, HCG, uE3 and Inhibin-A are reported in different studies.

180

181

182

183

184

185

186

187

188

189

190

191

192

193

First Brock et. al (1997) researched the presence of relation between maternal AFP level and low birth weight and reported 2.5 times more low birth weight for the cases where the AFP values are over 2.3 threshold value. Hamilton et. al. (1985) who considered AFP threshold value as 2.5 MoM, reported 10 times lower birth rate, 10 times more preterm activity risk, 3 times more ablatio placenta risk and 8 times more perinatal death risk for the cases with AFP levels over this threshold value. In our study AFP values are observed as ≤ 1.5 MoM for 47(94.0%) for pregnancies with complication against 3 (6.0%) pregnancies without complication with AFP values as > 1.5 MoM. If we consider AFP threshold values as 2 and 2.5 MoM, we observed < 49 (98.0%) and 1 (2%) complicated pregnancies for the both two truncations. No statistically significant risk increase found. In our study, this kind of a risk increase were not identified however the reason behind this might be because of our study with low risk population. No significant increase in the risk observed in our study between normal and low birth weight for the whole AFP MoM threshold values in our study (1.5, 2.0 and 2.5). In most of the studies, 2 or 2.5 MoM levels used as truncation values for describing the higher AFP status. We did not find any

194 high risk relation between AFP values and pregnancy complications as IUGR, Preterm Activity-
195 Birth, GDM, EMR, and preeclampsia.

196 Relation between secondary trimester maternal serum HCG level and pregnancy
197 complications drew attention of the many researchers. Abnormal increase in HCG levels might
198 result in decrease of the placental perfusion by decreasing the oxygenation of cytotrophoblast.
199 Lieppman et. al. (1993) used 2 MoM as the threshold value and reported 2, 8 times increased rate
200 of premature birth risk, 4 times increased low birth weight risk for the gravids over this threshold
201 value. In our study, we identified 37 (84.0%) complicated pregnancies with HCG threshold value
202 of ≤ 1.5 MoM against 13 (16.0%) complicated pregnancies with HCG value of > 1.5 MoM. By
203 considering HCG threshold value as < 2 Mom, we identified 46 (92.0%) complicated pregnancies
204 and identified 4 (8.0%) complicated pregnancies as we considered threshold value as > 2 MoM.
205 No statistically significant risk increase found. This kind of risk were not identified in our study.
206 In most of the studies, 2 or 2.5 MoM levels used as truncation values for describing the higher
207 HCG status. We did not find any high risk related between HCG values and pregnancy
208 complications as IUGR, Preterm Activity-Birth, GDM, EMR, and preeclampsia.

209 Two mechanisms asserted regarding higher HCG levels. First theory is "reactive
210 hyperplasia of the cytotrophoblastic cells exposed to hypoxia". According to an another
211 hypothesis, weight and volume of the placenta is greater in the cases where the HCG levels
212 increased, and as a result it might be reflecting a healthier placental implantation with bigger
213 babies (Sayin et. al., 2008). However, Mikic et. al. (1999), claimed that higher isolated maternal
214 serum beta-hCG levels are not an indicator for other pregnancy complications and IUGG.

215 We did not find any statistically significant relationship between serum HCG levels and
216 pregnancy results as similar to Johnson et al. In our study, we identified 37 (84. 0%) complicated
217 pregnancies with HCG threshold value of ≤ 1.5 MoM against 13 (16.0%) complicated
218 pregnancies with HCG value of > 1.5 MoM. By considering HCG threshold value as < 2 MoM,
219 we identified 46 (92.0%) complicated pregnancies and identified 4 (8.0%) complicated
220 pregnancies as we considered threshold value as > 2 MoM. No statistically significant risk
221 increase found. No comparison between these groups conducted as a result of having low
222 number of patients with AFP and HCG values of 2.5 MOM. Our study needs to be supported
223 by increasing the number of patients and conducting prospective studies.

224 Smith et. al. (2007). compared the PAPP-A and β -hCG values with pregnancy results in
225 8839 gravids which were in their 8th and 14th weeks, and stated that gravids with PAPP-A values

226 lower than 5 % are exposed to IUGR, premature birth, preeclampsia and stillbirth risks while for
227 the gravids with free β -hCG values below 5 percentile are exposed to IUGR risk. Huang et. al.
228 (2010) in their retrospective compositions including 141698 gravids, relation between
229 biochemical indicators obtained during first and secondary trimester and Down Syndrome
230 screening and pregnancy results and as compared with the control group AFP and total hCG
231 levels found to be significantly higher in terms of preeclampsia, IUGR and fetal loss while PAPP-
232 A and oestriol levels found to be significantly lower. In an another retrospective cohort study
233 conducted with 2844 cases multiple of Median (MoM) value for β -hCG and PAPP-A found to be
234 lower compared to control group in terms of preeclampsia, premature birth, IUGR and
235 decollement placenta cases (Ranta et. al., 2011). In some studies for the PAPP-A MoM value
236 inspected between 11th and 13th pregnancy week, thus reported to be lower compared to control
237 cases in terms of preeclampsia (Carbone et. al., 2011; Poon et. al., 2010), in some cases no
238 differences between the groups were found (Mikat et. al., 2012; Vandenberghe et. al., 2011), and
239 screening performance of serum PAPP-A for early start preeclampsia and IUGR reported as
240 week (Vandenberghe et. al., 2011).

241 In addition to AFP and hCG results, there are limited number of studies conducted on
242 researching the relation between uE3 levels and pregnancy complications. Pergament et. al.
243 (1995) considered the threshold value as 0.75 for trimester screening and pregnancy complication
244 values and found the occurrence of intrauterine growth deficiency to be more frequent for the
245 gravids whom have MoM levels below the threshold value. Kowalczyk et. al. (1998) reported that
246 the occurrence of intrauterine growth deficiency and oligohydramnios to be significantly more
247 frequent for the gravids with uE3 levels below 0.75 MoM threshold value. Ben et. al. (1996),
248 reported that more number of bad pregnancy results observed in the cases with higher secondary
249 trimester AFP and HCG levels. In a similar study like ours which were conducted in Turkey, no
250 relation between lower indirect oestriol levels with preterm activity, IUGR, macrosomia, fetal
251 distress found only, but a relation with GDM were found for uE3 \leq 0.5 MoM. In our study, we
252 identified 3 (6.0%) complicated pregnancies with uE3 threshold value of \leq 0.6 MoM against 47
253 (94.0%) complicated pregnancies with hCG value of $>$ 0.6 MoM. We did not identified a
254 statistically significant increase in preterm activity, IUGR, macrosomia and EMR.

255 Inhibin-A is known as the only roaming mature inhibin type during pregnancy. In the
256 published articles Tul et. al. (2003) reported a significant relationship between higher Inhibin-a
257 levels and preterm birth. Diagnosis of preeclampsia were left for the weeks between 20 and 22 as
258 the preeclampsia symptoms usually develop during late secondary trimester and 3rd trimester. ,

259 In an another study, a relation between the high levels of Inhibin-A in mother's serum in
260 secondary trimester and preeclampsia and IUGR (D'Anna et. al, 2002). Lambert-Messerlian et al
261 (2000) stated that, for the cases in secondary trimester with higher Inhibin-A and hCG levels
262 developed a high rate of late start preeclampsia while stating Inhibin-A's superiority for
263 identifying early start preeclampsia. In our study we identified 44 (89.2%) complicated cases with
264 Inhibin-A MoM values <2 and 6 (10.2%) cases with Inhibin-A MoM values with > 6 while there
265 is not a significant relationship if threshold value for Inhibin-A MoM considered as 2.0.
266 (p=0.910). In our study, we did not find high risk related with inhibin a for the pregnancy
267 complications as IUGR, preterm activity-birth, GDM, EMR and preeclampsia.

268 Spencer et al. (2006) conducted a case control study comprised of 24 cases with
269 developed preeclampsia and 144 normotensive cases. PAPP-A, free β -HCG activine A, inhibin A
270 levels were inspected in the cases between 22nd and 25th pregnancy weeks, a significant increase
271 found for group which developed preeclampsia compared to control group in terms of serum
272 PAPP-A, free β -hCG, activine A and activine B levels. Lower levels of PAPP-A (<0.4 MoM)
273 and hCG (<0.5 MoM) levels in first trimester, higher levels of AFP (>2.5 MoM), HCG (>3
274 MoM), inhibin A (≥ 2 MoM) and lower levels of AFP (<0.25 MoM), E3 (< 0.5 MoM) in
275 secondary trimester are reported to be in relation with increased pregnancy complications, but at
276 the same time it was reported that these indicators have lower sensitivity for identifying obstetric
277 complications and having high rate of false positive identifications; and if high levels of AFP is
278 present in secondary or third trimester with placenta praevia, placenta acreata, increata, percreata
279 should be suspected (Gagnon et. al., 2008).

280 Dugoff et. al. (2005) for the 33145 cases where AFP, hCG, E3 and Inhibin A inspected;
281 reported increased pregnancy complications where one of the values are abnormal while reported
282 increased pregnancy complications with increased significance in the presence of more than one
283 abnormal parameters. However, the sensitivity of these parameters for identifying the pregnancy
284 complications is low.

285

286 **Conclusion**

287

288 No significant relation between threshold values of AFP, hCG, uE3 and inhibin A which
289 are used in quad test as secondary trimester serum indicators in low risk populations and
290 pregnancy complications. In order the decrease bad fetomaternal results, more prospective
291 studies including bigger populations with greater number of patients required to be conducted
292 regarding increasing the fetal survival.

Effects of Secondary Trimester Maternal Serum Fetoprotein, Human Chorionic Gonadotropin, Unconjugated Oestriol, Inhibin-A Levels on the Results of Pregnancy

ORIGINALITY REPORT

6%

SIMILARITY INDEX

PRIMARY SOURCES

- 1 Cihan Aygül, Ramazan Özyurt, Bulat Aytek Şık, Serkan Kumbasar. "Evaluation of the efficacy of transobturator tape surgery in the treatment of stress urinary incontinence using urodynamics and questionnaires", *Journal of Turkish Society of Obstetric and Gynecology*, 2016
Crossref 55 words — 1%
- 2 www.tajev2016.org
Internet 31 words — 1%
- 3 www.konuralptipdergi.duzce.edu.tr
Internet 29 words — 1%
- 4 Grinshpun-Cohen, Julia, Talya Miron-Shatz, Michal Berkenstet, and Elon Pras. "The limited effect of information on Israeli pregnant women at advanced maternal age who decide to undergo amniocentesis", *Israel Journal of Health Policy Research*, 2015.
Crossref 27 words — 1%
- 5 www.mdpi.com
Internet 21 words — < 1%
- 6 Yur-Ren Kuo. "Microsurgical Tissue Transfers for Head and Neck Reconstruction in Patients with Alcohol-Induced Mental Disorder", *Annals of Surgical Oncology*, 01/2008
Crossref 13 words — < 1%
- 7 Singh, SD, S Shrestha, and SB Marahatta. "Incidence and risk

factors of low birth weight babies born in Dhulikhel Hospital", Journal of Institute of Medicine, 2011. 13 words — < 1 %
Crossref

8 www.ncbi.nlm.nih.gov/pmc/articles/PMC3071111/ 13 words — < 1 %
Internet

9 www.dovepress.com 10 words — < 1 %
Internet

10 srb.org.au 10 words — < 1 %
Internet

11 www.researchgate.net 10 words — < 1 %
Internet

12 Nasser Thweib. "Quality of Life of Palestinian Cancer Patients :", Journal of Pediatric Hematology/Oncology, 04/2011 9 words — < 1 %
Crossref

13 analefs.ro 9 words — < 1 %
Internet

14 Juan P. Cata. "Successful Extubation in the Operating Room After Infratentorial Craniotomy : The Cleveland Clinic Experience", Journal of Neurosurgical Anesthesiology, 01/2011 9 words — < 1 %
Crossref

15 Nutrition and Diet in Menopause, 2013. 9 words — < 1 %
Crossref

16 sogc.org 9 words — < 1 %
Internet

17 Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology, 2008. 8 words — < 1 %
Crossref

18 www.aafp.org
Internet

8 words — < 1%

19 Yaron, Y.. "Second-trimester maternal serum marker screening: Maternal serum @a-fetoprotein, @b-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome", American Journal of Obstetrics and Gynecology, 199910

7 words — < 1%

Crossref

20 Derbent, Aysel Uysal, Filiz Fatma Yanik, İlknur İnegöl Gümüş, Serap Simavli, and Nilgün Öztürk Turhan. "Impact of inherited thrombophilias on first and second trimester maternal serum markers for aneuploidy", The Journal of Maternal-Fetal & Neonatal Medicine, 2012.

6 words — < 1%

Crossref

EXCLUDE QUOTES OFF
EXCLUDE BIBLIOGRAPHY OFF

EXCLUDE MATCHES OFF